NHS National Framework for Transition Products (Nintedanib and Dalbavancin)
NHS England is establishing a national framework to supply two transition products: Nintedanib and Dalbavancin. The framework runs from May 2026 with varying end dates by region (9 to 17 months), with an option to extend up to 24 months.
- Closed28 January 2026
- Value£116m
- Per lot£39m across 3 lots
- BuyerNHS England
- WhereNHS England regions
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a licensed pharmaceutical supplier with the capability to distribute Nintedanib and Dalbavancin across one or more NHS England regions
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Dr Reddy's Laboratories, Novartis Pharmaceuticals UK, Pfizer, and Teva UK won the preceding Transition Products framework (Axitinib and Eltrombopag) in September 2025. Inferred from prior awards to this buyer, not confirmed.